Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
- PMID: 12893748
- DOI: 10.1182/blood-2003-04-1205
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma
Abstract
In this article, we report on 904 patients undergoing transplantation for follicular lymphoma. A total of 176 (19%) received allogeneic, 131 (14%) received purged autologous, and 597 (67%) received unpurged autologous transplants. Five-year treatment-related mortality (TRM) rates were 30%, 14%, and 8% and 5-year recurrence rates were 21%, 43%, and 58% after allotransplantation, purged autotransplantation, and unpurged autotransplantation, respectively. In multivariate analyses, allotransplantation had higher TRM and lower disease recurrence. Purged autotransplantation had a 26% lower recurrence risk than unpurged autotransplantation. Five-year probabilities of survival were 51%, 62%, and 55% after allogeneic, purged autotransplantation, and unpurged autotransplantation, respectively. Advanced age, prolonged interval from diagnosis to transplantation, high lactate dehydrogenase (LDH), refractory disease, bone marrow involvement, low performance scores, and transplantation between 1990 and 1993 were associated with adverse outcomes. Total body irradiation was associated with higher TRM but lower recurrence. There was no association between acute or chronic graft-versus-host disease and recurrence after allotransplantation. We conclude that both allogeneic and autologous transplantation can induce durable remissions. There may be a benefit to graft purging in autologous transplantation. The decreased recurrence after allotransplantation is offset by increased TRM. We did not detect a correlation between graft-versus-host disease (GVHD) and recurrence. Finally, outcomes of transplantation for follicular lymphoma show improvement over the past decade.
Similar articles
-
Syngeneic hematopoietic stem-cell transplantation for non-Hodgkin's lymphoma: a comparison with allogeneic and autologous transplantation--The Lymphoma Working Committee of the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation.J Clin Oncol. 2003 Oct 15;21(20):3744-53. doi: 10.1200/JCO.2003.08.054. Epub 2003 Sep 8. J Clin Oncol. 2003. PMID: 12963703
-
The potential benefit of allogeneic over autologous transplantation in patients with very early relapsed and refractory follicular lymphoma with prior remission duration of ≤12 months.Br J Haematol. 2016 Apr;173(2):260-4. doi: 10.1111/bjh.13947. Epub 2016 Feb 5. Br J Haematol. 2016. PMID: 26847389 Free PMC article.
-
Reduced-Intensity Conditioning with Fludarabine, Cyclophosphamide, and High-Dose Rituximab for Allogeneic Hematopoietic Cell Transplantation for Follicular Lymphoma: A Phase Two Multicenter Trial from the Blood and Marrow Transplant Clinical Trials Network.Biol Blood Marrow Transplant. 2016 Aug;22(8):1440-1448. doi: 10.1016/j.bbmt.2016.04.014. Epub 2016 Apr 23. Biol Blood Marrow Transplant. 2016. PMID: 27118571 Free PMC article. Clinical Trial.
-
The evolving role of autologous and allogeneic stem cell transplantation in follicular lymphoma.Blood Rev. 2006 Sep;20(5):235-44. doi: 10.1016/j.blre.2006.01.001. Epub 2006 Mar 2. Blood Rev. 2006. PMID: 16513231 Review.
-
Autologous and allogeneic stem cell transplantation in follicular lymphoma.Transfus Apher Sci. 2005 Feb;32(1):45-53. doi: 10.1016/j.transci.2004.10.005. Transfus Apher Sci. 2005. PMID: 15737873 Review.
Cited by
-
The role of rituximab in autologous and allogeneic hematopoietic stem cell transplantation for non-Hodgkin's lymphoma.Curr Hematol Malig Rep. 2006 Dec;1(4):220-9. doi: 10.1007/s11899-006-0003-x. Curr Hematol Malig Rep. 2006. PMID: 20425317 Review.
-
Clinical outcomes of allogeneic stem cell transplantation for relapsed or refractory follicular lymphoma: a retrospective analysis by the Fukuoka Blood and Marrow Transplantation Group.Int J Hematol. 2013 Oct;98(4):463-71. doi: 10.1007/s12185-013-1430-9. Epub 2013 Sep 17. Int J Hematol. 2013. PMID: 24043582
-
Investigational strategies in autologous stem cell transplantation for follicular lymphoma.Curr Oncol Rep. 2006 Sep;8(5):368-75. doi: 10.1007/s11912-006-0060-2. Curr Oncol Rep. 2006. PMID: 16901398 Review.
-
T cell depleted stem-cell transplantation for adults with hematologic malignancies: sustained engraftment of HLA-matched related donor grafts without the use of antithymocyte globulin.Blood. 2007 Dec 15;110(13):4552-9. doi: 10.1182/blood-2007-06-093880. Epub 2007 Aug 23. Blood. 2007. PMID: 17717135 Free PMC article. Clinical Trial.
-
Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation.Biometrics. 2008 Sep;64(3):733-740. doi: 10.1111/j.1541-0420.2007.00975.x. Epub 2008 Jan 11. Biometrics. 2008. PMID: 18190619 Free PMC article.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Miscellaneous